Raymond James Financial Inc. Buys Shares of 340,649 Certara, Inc. (NASDAQ:CERT)

Raymond James Financial Inc. bought a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 340,649 shares of the company's stock, valued at approximately $3,628,000. Raymond James Financial Inc. owned approximately 0.21% of Certara at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CERT. Brown Brothers Harriman & Co. lifted its stake in Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after purchasing an additional 1,487,998 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Certara by 169.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after buying an additional 1,253,385 shares during the period. ExodusPoint Capital Management LP acquired a new position in Certara in the 4th quarter valued at about $11,542,000. Teacher Retirement System of Texas raised its holdings in Certara by 13.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock valued at $48,542,000 after acquiring an additional 557,348 shares during the period. Finally, Norges Bank acquired a new stake in Certara during the fourth quarter worth approximately $2,932,000. Institutional investors own 73.96% of the company's stock.

Certara Stock Down 2.9 %

NASDAQ CERT traded down $0.41 during mid-day trading on Thursday, hitting $13.45. The company's stock had a trading volume of 1,532,151 shares, compared to its average volume of 1,234,034. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company's 50 day simple moving average is $11.67 and its 200 day simple moving average is $11.62. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -67.08, a PEG ratio of 9.29 and a beta of 1.64. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.94.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CERT shares. Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. KeyCorp boosted their price target on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. William Blair reiterated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Barclays lowered their price target on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, Stephens reiterated an "overweight" rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.